TABLE 1.
Antibiotic susceptibilities of 175 ABC baseline isolates from m-MITT patients in ATTACKa
| Antibacterial agent | MIC (µg/mL) | % NS (CLSI) | ||
|---|---|---|---|---|
| Range | MIC50 | MIC90 | ||
| Amikacin | 1 to >64 | >64 | >64 | 85 |
| Cefepime | 1 to >16 | >16 | >16 | 95 |
| Cefoperazone-sulbactam, 2:1 | 1 to >32 | 32 | >32 | NA |
| Colistin | ≤0.25 to >8 | 0.5 | >8 | 17b |
| Imipenem | 0.12 to >8 | >8 | >8 | 96 |
| Meropenem | 0.06 to >8 | >8 | >8 | 96 |
| Levofloxacin | 0.06 to >4 | >4 | >4 | 96 |
| Minocycline | ≤0.12 to >16 | 4 | 16 | 43 |
| Tigecycline | 0.06 to >4 | 1 | 2 | NA |
| Sulbactam | 1 to >64 | 32 | >64 | NA |
| Sulbactam-durlobactam | 0.25–16 | 2 | 4 | 4.6 |
a
ABC = Acinetobacter baumannii-calcoaceticus complex, which includes 175 out of the 183 isolates that were available for susceptibility testing at the Central Lab; CLSI = Clinical and Laboratory Standards Institute; NA = not applicable because CLSI breakpoints are not available; and NS = non-susceptible according to CLSI breakpoint criteria (12).
b
As no CLSI susceptible interpretive criteria exist for colistin (only intermediate and resistant), percent resistance is reported (12). Sulbactam-durlobactam was tested as a titration of sulbactam in the presence of 4 µg/mL durlobactam.